On May 26, 2021 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, reported that it will present at the Jefferies Virtual Healthcare Conference being held June 1-4, 2021 (Press release, Cue Biopharma, MAY 26, 2021, https://cuebiopharma.gcs-web.com/news-releases/news-release-details/cue-biopharma-present-corporate-and-clinical-progress-update [SID1234608278]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cue Biopharma will provide a corporate update highlighting clinical progress with CUE-101, representative of the CUE-100 series and the Company’s lead Immuno-STAT (Selective Targeting and Alteration of T cells) platform-based therapeutic, in clinical trials for the treatment of patients with HPV+ recurrent/metastatic head and neck cancer. The presentation will also focus on other platform developments as well as pipeline progress including CUE-102, Cue Biopharma’s drug candidate targeting Wilms Tumor 1 (WT1). CUE-102 is scheduled for an Investigational New Drug (IND) filing in 1H 2022.

Presentation Details
Jefferies Virtual Healthcare Conference
Date and Time: Thursday, June 3, 2021 at 8:30 a.m. EDT
Webcast link: https://protect-us.mimecast.com/s/ZywXCrkNz7tw9D5fLtfAM

A live and archived webcast of the presentation will be available in the Investors and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.